German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.
Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
Rare diseases specialist Swedish Orphan Biovitrum (Sobi) agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.
Eli Lilly and Company and Avidity Biosciences Inc. announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications.
Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Pfizer Inc. announced that the company will organize into three businesses: Innovative Medicines, Established Medicines, and Consumer Healthcare.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Company Also Bolsters Board of Directors and Scientific Advisory Board with Outstanding Leaders BOSTON–(BUSINESS WIRE)–SQZ Biotech (SQZ) announced today a partnership with Roche to develop a cell therapy platform that […]
11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the […]
